Evidence map›Paper›PMID 32467007›Full record

ArticleTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2020

Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.

Yujie Kong, Chen Cai, Li Ling, Li Zeng, Meihong Wu, Yanyun Wu, Wei Zhang, Zhong Liu

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 10 pooled it
1.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 10 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Treatment of immunocompromised COVID-19 patients with convalescent plasma.Transplant infectious disease : an official journal of the Transplantation Society · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Yujie KongClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, 610052, Chengdu, Sichuan Province, PR China; Key laboratory of transfusion adverse reactions, CAMS, 610052, Chengdu, Sichuan Province, PR China.
Chen CaiDepartment of Special Clinic, First affiliated hospital, the Second Military Medical University, Shanghai, 200433, Shanghai, PR China; Guanggu District, the Maternal and Child Health Hospital of Hubei Province, 430070, Wuhan, Hubei Province, PR China.
Li LingClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, 610052, Chengdu, Sichuan Province, PR China; Key laboratory of transfusion adverse reactions, CAMS, 610052, Chengdu, Sichuan Province, PR China.
Li ZengGuanggu District, the Maternal and Child Health Hospital of Hubei Province, 430070, Wuhan, Hubei Province, PR China; Department of Organ Transplantation, First affiliated hospital, the Second Military Medical University, Shanghai, 200433, Shanghai, PR China.
Meihong WuGuanggu District, the Maternal and Child Health Hospital of Hubei Province, 430070, Wuhan, Hubei Province, PR China; Department of oncology, First affiliated hospital, the Second Military Medical University, Shanghai, 200433, Shanghai, PR China.
Yanyun WuUniversity of Miami, Miami, Florida, United States.
Wei ZhangGuanggu District, the Maternal and Child Health Hospital of Hubei Province, 430070, Wuhan, Hubei Province, PR China; Department of Respiratory and Critical Care Medicine, First affiliated hospital, the Second Military Medical University, Shanghai, 200433, Shanghai, PR China. Electronic address: zhangweismmu@126.com.
Zhong LiuClinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, 610052, Chengdu, Sichuan Province, PR China; Key laboratory of transfusion adverse reactions, CAMS, 610052, Chengdu, Sichuan Province, PR China. Electronic address: liuz@ibt.pumc.edu.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNHubei Provincial Women and Children's Hospital · CNSecond Military Medical University · CNUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBecause treatment options for coronavirus disease 2019 (COVID-19) are very limited, the use of convalescent plasma has bee explored. CASE PRESENTATION AND TREATMENT: A male centenarian with cough and dyspnea for 2 months was diagnosed with COVID-19. Without effective treatments and with the increased risks of antiviral therapy for the elderly, this patient was given convalescent plasma. The viral load, complete blood count, inflammatory indicators, vital signs, and clinical symptoms were observed before and after COVID-19 convalescent plasma transfusion.

resultsAfter convalescent plasma transfusion, significant improvement was observed on laboratory indicators and clinical symptoms of the patient. Concurrently, SARS-CoV-2 viral load decreased sharply after the first transfusion (from 2.55 × 104 to 1.39 × 103 copies/mL) and became undetectable after the second transfusion.

conclusionsWith the substantial increase of COVID-19 in recent months,treatment for elderly patients has become restricted in some countries. The successful treatment of this 100-year-old patient using convalescent plasma suggests that we should consider adding convalescent plasma in th management of the elderly.

Indexed as

Aged, 80 and overCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveMalePatient AdmissionSARS-CoV-2Treatment Outcomeconvalescent plasmaCoronavirus Disease 2019transfusion

Identifiers

PMID32467007
PMCPMC7239781
OpenAlexW3026647609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.